LONG-TERM EFFECTS OF A CONVERTING-ENZYME-INHIBITOR AND A CALCIUM-CHANNEL BLOCKER ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL-HYPERTENSION

被引：40

作者：

BIGAZZI, R

BIANCHI, S

BALDARI, D

SGHERRI, G

BALDARI, G

CAMPESE, VM

机构：

[1] UO di Nefrologia e Dialisi, Spedali Riuniti, Livorno

[2] Division of Nephrology, University of Southern California, Los Angeles, CA

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 02期

关键词：

ESSENTIAL HYPERTENSION; MICROALBUMINURIA; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; ENALAPRIL; NICARDIPINE;

D O I：

10.1093/ajh/6.2.108

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Microalbuminuria in patients with essential hypertension is associated with increased incidence of cardiovascular morbidity and mortality. Reduction of urinary albumin excretion (UAE) with therapy could reduce cardiovascular events. The long-term effect of commonly used antihypertensive agents on UAE has not been properly investigated. In the present study, we have prospectively studied the effects of therapy for 24 months with a converting enzyme inhibitor, enalapril, or a calcium channel blocker, nicardipine, on UAE in 40 patients with essential hypertension and microalbuminuria. Enalapril and nicardipine were equally effective in reducing arterial pressure. However, enalapril decreased UAE from 77.1 +/- 10.4 to 30.4 +/- 7.9 mg/24 h after 1 year, and to 24.7 +/- 4.8 (P < .01) after 2 years of therapy. UAE however, did not change in patients treated with nicardipine (from 65.2 +/- 12 to 73 +/- 14 after 1 year, and to 52.7 +/- 21 mg/24 h after 2 years of therapy). The impact of reducing UAE on overall cardiovascular morbidity and mortality and on future progression of renal failure in patients with essential hypertension remains to be established.

引用

页码：108 / 113

页数：6

共 45 条

[1] Bigazzi R., Bianchi S., Baldari G., Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension, Nephron, 61, pp. 94-97, (1992)
[2] Parving H.H., Jensen H.E., Mogensen C.E., Evrin P.E., Increased urinary albumin excretion in benign essential hypertension, Lancet, 1, pp. 231-237, (1974)
[3] Losito A., Fortunati F., Zampi I., Del Favero A., Impaired functional reserve and albuminuria in essential hypertension, Br Med J, 296, pp. 1562-1564, (1988)
[4] Giaconi S., Levanti C., Fommei E., Et al., Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension, Am J Hypertens, 2, pp. 259-261, (1989)
[5] Pedersen E.B., Mogensen C.E., Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate and renal plasma flow in patients with essential hypertension, Scand J Clin Lab Invest, 36, pp. 231-237, (1976)
[6] Parving H.H., Oxenboll B., Svendsen P.A., Et al., Early detection of patients at risk of developing diabetic nephropathy: A longitudinal study of urinary albumin excretion, Acta Endocrinol, 100, pp. 550-555, (1982)
[7] Viberti G.C., Hill R.D., Jarret R.D., Et al., Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus, Lancet, 1, pp. 1430-1432, (1982)
[8] Mogensen C.E., Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes, N Engl J Med, 310, pp. 356-360, (1986)
[9] Lewin A., Blaufox D., Castle H., Et al., Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program, Arch Intern Med, 145, pp. 424-427, (1985)
[10] Samuelsson O., Wilhelmsen L., Elmfeldt D., Et al., Predictors of cardiovascular morbidity in treated hypertension results from the primary preventive trial in Goteborg, Sweden, J Hypertens, 3, pp. 167-176, (1985)

← 1 2 3 4 5 →